88 related articles for article (PubMed ID: 29025983)
1. Predictive Value of
Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of
Saponjski J; Macut D; Saranovic DS; Radovic B; Artiko V
Radiol Oncol; 2020 Nov; 55(1):18-25. PubMed ID: 33885241
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
[No Abstract] [Full Text] [Related]
5. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.
Treglia G; Rufini V; Piccardo A; Imperiale A
Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
[TBL] [Abstract][Full Text] [Related]
6. [
Zhi Y; Higuchi T; Hackenberg S; Hagen R; Stöth M; Scherzad A; Buck AK; Werner RA; Serfling SE
Endocrine; 2024 May; 84(2):656-662. PubMed ID: 38133766
[TBL] [Abstract][Full Text] [Related]
7. Use of Neoadjuvant Vandetanib in Aggressive Pediatric Medullary Thyroid Carcinoma.
Kothari R; Kreimer S; Nadel H; Seeley H; Hartman G; Meister KD
JCO Precis Oncol; 2024 Jan; 8():e2300257. PubMed ID: 38207224
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
[No Abstract] [Full Text] [Related]
9. An audit of medullary thyroid carcinoma from a tertiary care hospital in northwest India.
Chakraborty AM; Rai A; Pal R; Mukherjee S; Dahiya D; Kumar R; Saikia UN; Panda NK; Bhadada SK; Dutta P
Front Endocrinol (Lausanne); 2023; 14():1226348. PubMed ID: 38260132
[TBL] [Abstract][Full Text] [Related]
10. Small Cell Neuroendocrine Carcinoma of the Prostate on 18 F-DCFPyL and 18 F-FDG PET/CT.
Li E; Russon A; Chen J; Mansberg V; Mansberg R
Clin Nucl Med; 2024 Apr; 49(4):335-337. PubMed ID: 38377379
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.
Imperiale A; Berti V; Burgy M; Cazzato RL; Piccardo A; Treglia G
Rev Endocr Metab Disord; 2024 Feb; 25(1):187-202. PubMed ID: 37715050
[TBL] [Abstract][Full Text] [Related]
12. Correlation of
Ueda CE; Flausino Dias L; de Godoi Carneiro C; Sapienza MT; Alberto Buchpiguel C; Schiavom Duarte P
Arch Endocrinol Metab; 2024 Apr; 68():e230152. PubMed ID: 38602746
[TBL] [Abstract][Full Text] [Related]
13. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports.
Moog S; Lamartina L; Bani MA; Al Ghuzlan A; Friboulet L; Italiano A; Lacroix L; Postel Vinay S; Tselikas L; Deschamps F; Bonnet B; Pani F; Baudin E; Hadoux J
Thyroid; 2023 Nov; 33(11):1368-1373. PubMed ID: 37698883
[No Abstract] [Full Text] [Related]
14. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.
Lacouture ME; Ciccolini K; Kloos RT; Agulnik M
Thyroid; 2014 Sep; 24(9):1329-40. PubMed ID: 24902006
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma (MTC): unusual metastatic sites.
Kazakou P; Simeakis G; Alevizaki M; Saltiki K
Endocrinol Diabetes Metab Case Rep; 2021 Sep; 2021():. PubMed ID: 34551391
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two region of interest definition methods for metabolic response evaluation with [18F]FDG-PET.
Vriens D; De Geus-Oei LF; Van Laarhoven HW; Van Der Heijden HF; Krabbe PF; Visser EP; Oyen WJ
Q J Nucl Med Mol Imaging; 2010 Sep; ():. PubMed ID: 20827254
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer.
Xian TC; Yang MY; Zhang XL; Wang J; Luo Y
Horm Metab Res; 2024 Jan; ():. PubMed ID: 38278145
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed on
Pereira M; Shivdasani D; Singh N
Indian J Nucl Med; 2021; 36(4):432-434. PubMed ID: 35125763
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Superscan in Medullary Thyroid Carcinoma: A Rare Presentation in [
Abdlkadir AS; Al-Adhami D; Alsyouf B; Alhouwari R; Al-Rasheed U; Jaber O; Mohamad I; Al-Ibraheem A
Nucl Med Mol Imaging; 2024 May; 58(3):147-149. PubMed ID: 38633289
[No Abstract] [Full Text] [Related]
20. Volumetric and texture analysis of pretherapeutic
Werner RA; Bundschuh RA; Higuchi T; Javadi MS; Rowe SP; Zsótér N; Kroiss M; Fassnacht M; Buck AK; Kreissl MC; Lapa C
Endocrine; 2019 Feb; 63(2):293-300. PubMed ID: 30206772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
